Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.

@article{Bumer2015AntibodymediatedDO,
  title={Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.},
  author={Sebastian B{\"a}umer and Nicole B{\"a}umer and Neele Appel and Lisa Terheyden and Julia Fremerey and Sonja Schelhaas and Eva Wardelmann and Frank Buchholz and Wolfgang E. Berdel and Carsten M{\"u}ller-Tidow},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2015},
  volume={21 6},
  pages={1383-94}
}
PURPOSE KRAS mutations are frequent driver mutations in multiple cancers. KRAS mutations also induce anti-EGFR antibody resistance in adenocarcinoma such as colon cancer. The aim of this study was to overcome anti-EGFR antibody resistance by coupling the antibody to KRAS-specific siRNA. EXPERIMENTAL DESIGN The anti-EGFR antibody was chemically coupled to siRNA. The resulting complex was tested for antibody binding efficiency, serum stability and ability to deliver siRNA to EGFR-expressing… CONTINUE READING
12 Citations
53 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 53 references

Similar Papers

Loading similar papers…